EC 200-318-1
Also known as leurocristine.
Phase 3 trial of subcutaneous T‑cell‑engaging bispecific with R‑CHOP cut progression/death risk by 51% in newly diagnosed DLBCL (IPI 2–5); safety consistent with known profiles.
The trial's sole U.S. primary endpoint—overall survival—did not reach statistical significance; additional results will be submitted for peer review.
